CD44
Basic information
Region (hg38): 11:35138882-35232402
Previous symbols: [ "MIC4", "MDU2", "MDU3" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Blood group, Indian | BG | Hematologic | Variants associated with a blood group may be important in specific situations (eg, related to transfusion) | Hematologic | 1146277; 8636151 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CD44 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 13 | |||||
missense | 30 | 38 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 1 | 3 | |||
non coding | 4 | |||||
Total | 0 | 0 | 31 | 12 | 12 |
Variants in CD44
This is a list of pathogenic ClinVar variants found in the CD44 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-35139361-G-A | not specified | Uncertain significance (Aug 04, 2023) | ||
11-35150575-G-A | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35153498-T-C | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35158104-G-A | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35163005-A-T | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35166644-G-A | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35169898-C-G | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35170667-G-A | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35170732-A-G | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35171082-C-T | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35176617-A-C | not specified | Uncertain significance (Jan 24, 2023) | ||
11-35176643-C-T | not specified | Uncertain significance (Mar 17, 2023) | ||
11-35176644-G-A | INDIAN BLOOD GROUP SYSTEM POLYMORPHISM | Benign (Jan 15, 1994) | ||
11-35176654-C-T | Likely benign (May 25, 2018) | |||
11-35176696-G-T | not specified | Uncertain significance (May 08, 2024) | ||
11-35179369-G-A | Calcium oxalate urolithiasis | association (Mar 01, 2014) | ||
11-35180295-C-T | CD44-related disorder | Benign (Oct 21, 2019) | ||
11-35180309-G-A | not specified | Uncertain significance (May 12, 2024) | ||
11-35180369-A-G | not specified | Uncertain significance (Jan 04, 2024) | ||
11-35180385-C-T | Likely benign (May 24, 2018) | |||
11-35180414-T-C | Benign (Jul 23, 2018) | |||
11-35189836-T-G | Likely benign (Jul 21, 2018) | |||
11-35189886-C-T | not specified | Uncertain significance (Sep 27, 2021) | ||
11-35189887-G-A | CD44-related disorder | Benign (Jul 23, 2018) | ||
11-35189914-C-A | not specified | Uncertain significance (Feb 05, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CD44 | protein_coding | protein_coding | ENST00000428726 | 18 | 93533 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.45e-7 | 1.00 | 125637 | 0 | 110 | 125747 | 0.000437 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.842 | 358 | 406 | 0.882 | 0.0000206 | 4882 |
Missense in Polyphen | 84 | 116.28 | 0.72241 | 1369 | ||
Synonymous | -0.0275 | 145 | 145 | 1.00 | 0.00000775 | 1399 |
Loss of Function | 3.25 | 18 | 40.2 | 0.448 | 0.00000206 | 461 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00122 | 0.00122 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00229 | 0.00229 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000195 | 0.000193 |
Middle Eastern | 0.00229 | 0.00229 |
South Asian | 0.000163 | 0.000163 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Adhesion with HA plays an important role in cell migration, tumor growth and progression. In cancer cells, may play an important role in invadopodia formation. Also involved in lymphocyte activation, recirculation and homing, and in hematopoiesis. Altered expression or dysfunction causes numerous pathogenic phenotypes. Great protein heterogeneity due to numerous alternative splicing and post-translational modification events. Receptor for LGALS9; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity). {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:16541107}.;
- Pathway
- ECM-receptor interaction - Homo sapiens (human);Shigellosis - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Hematopoietic cell lineage - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);Hepatitis C and Hepatocellular Carcinoma;Wnt Signaling Pathway and Pluripotency;Senescence and Autophagy in Cancer;Neutrophil degranulation;Hyaluronan uptake and degradation;Hyaluronan metabolism;Metabolism of carbohydrates;Cytokine Signaling in Immune system;Integrin cell surface interactions;Glycosaminoglycan metabolism;Extracellular matrix organization;Innate Immune System;Immune System;Metabolism;Integrin;TGF_beta_Receptor;Cell surface interactions at the vascular wall;Hemostasis;Degradation of the extracellular matrix;Interferon gamma signaling;Wnt Canonical;Osteopontin-mediated events;Interferon Signaling;Wnt Mammals
(Consensus)
Recessive Scores
- pRec
- 0.949
Intolerance Scores
- loftool
- 0.890
- rvis_EVS
- 0.23
- rvis_percentile_EVS
- 68.52
Haploinsufficiency Scores
- pHI
- 0.161
- hipred
- Y
- hipred_score
- 0.598
- ghis
- 0.473
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.492
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cd44
- Phenotype
- pigmentation phenotype; neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; renal/urinary system phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; digestive/alimentary phenotype; muscle phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype;
Gene ontology
- Biological process
- inflammatory response;cell adhesion;cell-matrix adhesion;extracellular matrix disassembly;extracellular matrix organization;hyaluronan catabolic process;positive regulation of peptidyl-serine phosphorylation;positive regulation of heterotypic cell-cell adhesion;negative regulation of apoptotic process;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;neutrophil degranulation;negative regulation of DNA damage response, signal transduction by p53 class mediator;wound healing, spreading of cells;cellular response to fibroblast growth factor stimulus;positive regulation of peptidyl-tyrosine phosphorylation;leukocyte migration;cartilage development;interferon-gamma-mediated signaling pathway;positive regulation of ERK1 and ERK2 cascade;monocyte aggregation;cell-cell adhesion;positive regulation of monocyte aggregation;negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;regulation of lamellipodium morphogenesis
- Cellular component
- Golgi apparatus;cytosol;plasma membrane;integral component of plasma membrane;microvillus;focal adhesion;cell surface;basolateral plasma membrane;apical plasma membrane;secretory granule membrane;lamellipodium membrane;macrophage migration inhibitory factor receptor complex;cell projection;extracellular exosome
- Molecular function
- transmembrane signaling receptor activity;cytokine receptor activity;protein binding;collagen binding;hyaluronic acid binding